Table 1.
Characteristic | Ledipasvir–Sofosbuvir for 12 Wk (N = 335) |
---|---|
Median age (IQR) — yr | 52 (48–58) |
Male sex — no. (%) | 276 (82) |
Race — no. (%)† | |
White | 203 (61) |
Black | 115 (34) |
Asian | 6 (2) |
Other or unknown | 11 (3) |
Median body-mass index (IQR)‡ | 27 (24–30) |
HCV genotype — no. (%) | |
1a | 250 (75) |
1b | 77 (23) |
4 | 8 (2) |
Median HCV RNA (IQR) — log10 IU/ml | 6.9 (6.3–7.2) |
IL28B genotype — no. (%) | |
CC | 81 (24) |
CT | 185 (55) |
TT | 69 (21) |
Cirrhosis — no. (%) | 67 (20) |
Median CD4+ cell count (IQR) — cells/µl | 628 (469–823) |
Antiviral regimen — no. (%) | |
Efavirenz–emtricitabine–tenofovir DF | 160 (48) |
Raltegravir–emtricitabine–tenofovir DF | 146 (44) |
Rilpivirine–emtricitabine–tenofovir DF | 29 (9) |
HCV treatment history — no. (%) | |
No previous treatment | 150 (45) |
Previous treatment | 185 (55) |
DF denotes disoproxil fumarate, HVC hepatitis C virus, and IQR interquartile range.
Race was self-reported.
The body-mass index is the weight in kilograms divided by the square of the height in meters.